More than health risks play a role in compliance with coronavirus measures The risk of COVID-19 is not the only factor that determines compliance with the coronavirus measures; other risks also play a role.
No evidence of more serious illness from COVID-19 among Q fever patients There are no indications that people who previously had Q fever had a more serious course of illness from the coronavirus SARS-CoV-2. This is evident from RIVM research.
Specific group of patients with impaired immunity invited in October for third COVID-19 vaccination From 6 October on, a specific group of people with severely impaired immunity (immunocompromised patients) will receive their invitation for a third vaccination against COVID-19.
Number of STIs continues to rise at Dutch STI clinics In the first half of this year more STIs were found in people who have been tested at Dutch STI clinics. The increase pertains to all STIs, with the exception of HIV.
European Antibiotic Awareness Day 2016 Friday 18 November is European Antibiotic Awareness Day. On this day, throughout Europe attention focuses on the threat of antibiotic resistance to people and animals.
EU legislation genetically modified microbial biocontrol agents is fit for purpose EU legislative instruments are sufficient to ensure the safety of such products.
Surveillance and developments National Immunisation Programme 2015-2016 The report provides an overview of effectiveness and safety of vaccines and vaccine research.
RIVM starts field research into rubber granulate RIVM has started to take samples of rubber granulate from 100 synthetic turf fields in the Netherlands.
Need for strategy to assess endocrine disrupting chemicals There is a need for a strategy to enable companies and governments to assess whether chemicals are endocrine disrupting.